Cellebrite Investors Face Potential Class Action After Guidance Cut

The selloff was triggered by a series of disappointing financial disclosures. Cellebrite reported annual recurring revenue of approximately $507.8 million, falling short of the $510 million floor the company had previously set for investors. This miss was compounded by a reduction in full-year growth expectations; the company lowered its annual recurring revenue forecast from a previous range of $567–$573 million down to $550–$560 million.

Levi & Korsinsky is now probing whether Cellebrite provided materially misleading information regarding its growth trajectory and Inseyets conversion trends prior to the earnings announcement. The investigation aims to determine if shareholders were misled by previous statements on the company's financial health. Investors who purchased securities and incurred losses are being encouraged to submit their trade records for a potential recovery evaluation. The firm, which specializes in shareholder rights, has noted that eligibility for the inquiry is determined by purchase dates rather than current holding status.